omalizumab

Spain

Drugs containing this active substance

  • OMYCLO 150 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN

    It is used for the treatment of severe allergic asthma in adults and children (from 6 years of age), chronic rhinosinusitis with nasal polyps in adults, and chronic spontaneous urticaria in adults and adolescents (from 12 years of age).

    Form: solution for injection in pre-filled pen

    Active substance Dosage
    omalizumab 150 mg

    ATC: R03D R03DX R03DX05

    Manufacturer: Celltrion Healthcare Hungary Kft.

  • It is used for the treatment of severe allergic asthma in adults and children aged 6 years and older, chronic rhinosinusitis with nasal polyps in adults, and chronic spontaneous urticaria in adults and adolescents aged 12 years and older.

    Form: solution for injection in a pre-filled syringe

    Active substance Dosage
    omalizumab 150 mg

    ATC: R03D R03DX R03DX05

    Manufacturer: Celltrion Healthcare Hungary Kft.

  • It is used to treat severe allergic asthma in adults, adolescents, and children aged 6 years and older who are already using other medications, and to treat chronic rhinosinusitis with nasal polyps in adults aged 18 years and older.

    Form: solution for injection in a pre-filled syringe

    Active substance Dosage
    omalizumab 75 mg

    ATC: R03D R03DX R03DX05

    Manufacturer: Celltrion Healthcare Hungary Kft.

  • It is used for the treatment of severe allergic asthma in adults and children (from 6 years of age), chronic rhinosinusitis with nasal polyps in adults (from 18 years of age), and chronic spontaneous urticaria in adults and adolescents (from 12 years of age).

    Form: solution for injection in a pre-filled syringe

    Active substance Dosage
    omalizumab 150 mg

    ATC: R03D R03DX R03DX05

    Manufacturer: Novartis Europharm Limited

  • It is used for the treatment of severe allergic asthma in adults, adolescents, and children aged 6 years and older whose symptoms are not controlled with other medications. It is also used in adults (over 18 years old) to treat chronic rhinosinusitis with nasal polyps.

    Form: solution for injection in a pre-filled syringe

    Active substance Dosage
    omalizumab 75 mg

    ATC: R03D R03DX R03DX05

    Manufacturer: Novartis Europharm Limited